Custom dosing study aims to tame dangerous liver pressure

This small pilot study tested whether using a computer model to predict safe, personalized doses of the cholesterol drug simvastatin could help control portal hypertension in people with liver cirrhosis. Over three months, 22 patients with mild-to-moderate cirrhosis received either a 5 mg or 15 mg daily dose based on their liver function. Researchers monitored changes in liver blood flow and safety to see if this approach could be a useful treatment option.